Global Blood Therapeutics, Inc. (GBT)
Company Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development.
It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A.
to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 457 |
| CEO | Ted Love |
Contact Details
Address:
181 Oyster Point Blvd South San Francisco, California 94080 United States | |
| Phone | 650 741 7700 |
| Website | globalbloodtx.com |
Stock Details
| Ticker Symbol | GBT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001629137 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ted W. Love M.D. | President, Chief Executive Officer and Director |
| Jeffrey S. Farrow | Chief Financial Officer and Principal Accounting Officer |
| Jung E. Choi | Chief Business and Strategy Officer |
| David L. Johnson | Chief Commercial Officer |
| Dr. Kim Smith-Whitley M.D. | Executive Vice President and Head of Research & Development |
| Dr. David R. Phillips | Founder and Advisor |
| Dr. Matthew P. Jacobson Ph.D. | Founder and Advisor |
| Dr. Andrej Sali Ph.D. | Founder and Advisor |
| Nazila Habibizad | Executive Vice President of Operations |
| Stephanie Yao | Senior Director of Corporate Communications and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 22, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 22, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 17, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 16, 2022 | 4 | Statement of changes in beneficial ownership of securities |